IV Meloxicam Returns for Treatment of Pain

The FDA has approved Xifyrm (Azurity) and Qamzova (Nanjing Delova), two new intravenous (IV) formulations of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for use alone or in combination with non-NSAID analgesics for treatment of moderate to severe pain in adults. Anjeso, the first IV formulation of meloxicam, was discontinued in 2022 for commercial reasons.

Publication Details

Journal
˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Published
2025-09-29
DOI
https://doi.org/10.58347/tml.2025.1738b
Primary Topic
Pain Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IV Meloxicam Returns for Treatment of Pain

˜The œmedical letter on drugs and therapeutics/˜The œmedical letter
Pain Mechanisms and Treatments
article

IV Meloxicam Returns for Treatment of Pain

article en

Abstract

The FDA has approved Xifyrm (Azurity) and Qamzova (Nanjing Delova), two new intravenous (IV) formulations of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for use alone or in combination with non-NSAID analgesics for treatment of moderate to severe pain in adults. Anjeso, the first IV formulation of meloxicam, was discontinued in 2022 for commercial reasons.

˜The œmedical letter on drugs and therapeutics/˜The œmedical letterVol. 67(1738)
Openalex Percentile: Top 67%
Pain Mechanisms and Treatments
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

IV Meloxicam Returns for Treatment of Pain · ˜The œmedical letter on drugs and therapeutics/˜The œmedical letter (2025) | TGRS Research Map | TGRS